BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 27220764)

  • 21. Is tumor testing efficiency for Lynch syndrome different in rectal and colon cancer?
    Marabelli M; Gandini S; Rafaniello PR; Calvello M; Tolva G; Feroce I; Lazzeroni M; Marino E; Dal Molin M; Trovato C; Guerrieri-Gonzaga A; Petz WL; Barberis M; Bertario L; Bonanni B
    Dig Liver Dis; 2020 Dec; 52(12):1503-1511. PubMed ID: 32620519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening.
    Bessa X; Ballesté B; Andreu M; Castells A; Bellosillo B; Balaguer F; Castellví-Bel S; Paya A; Jover R; Alenda C; Titó L; Martinez-Villacampa M; Vilella A; Xicola RM; Pons E; Llor X;
    Clin Gastroenterol Hepatol; 2008 Feb; 6(2):206-14. PubMed ID: 18096441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features.
    Schiemann U; Müller-Koch Y; Gross M; Daum J; Lohse P; Baretton G; Muders M; Mussack T; Kopp R; Holinski-Feder E
    Digestion; 2004; 69(3):166-76. PubMed ID: 15118395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Redundant DNA methylation in colorectal cancers of Lynch-syndrome patients.
    Alemayehu A; Sebova K; Fridrichova I
    Genes Chromosomes Cancer; 2008 Oct; 47(10):906-14. PubMed ID: 18618713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microsatellite instability: an update.
    Yamamoto H; Imai K
    Arch Toxicol; 2015 Jun; 89(6):899-921. PubMed ID: 25701956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N_LyST: a simple and rapid screening test for Lynch syndrome.
    Susanti S; Fadhil W; Ebili HO; Asiri A; Nestarenkaite A; Hadjimichael E; Ham-Karim HA; Field J; Stafford K; Matharoo-Ball B; Hassall JC; Sharif A; Oniscu A; Ilyas M
    J Clin Pathol; 2018 Aug; 71(8):713-720. PubMed ID: 29472252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lynch-like syndrome is as frequent as Lynch syndrome in early-onset nonfamilial nonpolyposis colorectal cancer.
    Antelo M; Golubicki M; Roca E; Mendez G; Carballido M; Iseas S; Cuatrecasas M; Moreira L; Sanchez A; Carballal S; Castells A; Boland CR; Goel A; Balaguer F
    Int J Cancer; 2019 Aug; 145(3):705-713. PubMed ID: 30693488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment.
    Rigter LS; Snaebjornsson P; Rosenberg EH; Atmodimedjo PN; Aleman BM; Ten Hoeve J; Geurts-Giele WR; ; van Ravesteyn TW; Hoeksel J; Meijer GA; Te Riele H; van Leeuwen FE; Dinjens WN; van Leerdam ME
    Gut; 2018 Mar; 67(3):447-455. PubMed ID: 29439113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status.
    Oliveira C; Westra JL; Arango D; Ollikainen M; Domingo E; Ferreira A; Velho S; Niessen R; Lagerstedt K; Alhopuro P; Laiho P; Veiga I; Teixeira MR; Ligtenberg M; Kleibeuker JH; Sijmons RH; Plukker JT; Imai K; Lage P; Hamelin R; Albuquerque C; Schwartz S; Lindblom A; Peltomaki P; Yamamoto H; Aaltonen LA; Seruca R; Hofstra RM
    Hum Mol Genet; 2004 Oct; 13(19):2303-11. PubMed ID: 15294875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microsatellite instability, MLH1 promoter methylation, and BRAF mutation analysis in sporadic colorectal cancers of different ethnic groups in Israel.
    Vilkin A; Niv Y; Nagasaka T; Morgenstern S; Levi Z; Fireman Z; Fuerst F; Goel A; Boland CR
    Cancer; 2009 Feb; 115(4):760-9. PubMed ID: 19127559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor testing to identify lynch syndrome in two Australian colorectal cancer cohorts.
    Buchanan DD; Clendenning M; Rosty C; Eriksen SV; Walsh MD; Walters RJ; Thibodeau SN; Stewart J; Preston S; Win AK; Flander L; Ouakrim DA; Macrae FA; Boussioutas A; Winship IM; Giles GG; Hopper JL; Southey MC; English D; Jenkins MA
    J Gastroenterol Hepatol; 2017 Feb; 32(2):427-438. PubMed ID: 27273229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas.
    Farchoukh L; Kuan SF; Dudley B; Brand R; Nikiforova M; Pai RK
    Am J Surg Pathol; 2016 Oct; 40(10):1390-9. PubMed ID: 27438990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation.
    Snowsill T; Coelho H; Huxley N; Jones-Hughes T; Briscoe S; Frayling IM; Hyde C
    Health Technol Assess; 2017 Sep; 21(51):1-238. PubMed ID: 28895526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome.
    Rahner N; Friedrichs N; Steinke V; Aretz S; Friedl W; Buettner R; Mangold E; Propping P; Walldorf C
    J Pathol; 2008 Jan; 214(1):10-6. PubMed ID: 17973250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Constitutional MLH1 methylation presenting with colonic polyposis syndrome and not Lynch syndrome.
    Kidambi TD; Blanco A; Van Ziffle J; Terdiman JP
    Fam Cancer; 2016 Apr; 15(2):275-80. PubMed ID: 26781822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors.
    Lubomierski N; Plotz G; Wormek M; Engels K; Kriener S; Trojan J; Jungling B; Zeuzem S; Raedle J
    Cancer; 2005 Sep; 104(5):952-61. PubMed ID: 16015629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
    Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
    J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤ 70 years.
    Leenen CH; van Lier MG; van Doorn HC; van Leerdam ME; Kooi SG; de Waard J; Hoedemaeker RF; van den Ouweland AM; Hulspas SM; Dubbink HJ; Kuipers EJ; Wagner A; Dinjens WN; Steyerberg EW
    Gynecol Oncol; 2012 May; 125(2):414-20. PubMed ID: 22306203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population-based screening for Lynch syndrome in Western Australia.
    Schofield L; Grieu F; Amanuel B; Carrello A; Spagnolo D; Kiraly C; Pachter N; Goldblatt J; Platell C; Levitt M; Stewart C; Salama P; Ee H; Raftopoulous S; Katris P; Threlfall T; Edkins E; Wallace M; Iacopetta B
    Int J Cancer; 2014 Sep; 135(5):1085-91. PubMed ID: 24474394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study.
    Gausachs M; Mur P; Corral J; Pineda M; González S; Benito L; Menéndez M; Espinàs JA; Brunet J; Iniesta MD; Gruber SB; Lázaro C; Blanco I; Capellá G
    Eur J Hum Genet; 2012 Jul; 20(7):762-8. PubMed ID: 22274583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.